The regenerative potential of the heart is insufficient to fully restore functioning myocardium after injury, motivating the quest for a cell-based replacement strategy. Bone marrow-derived mesenchymal stem cells (MSCs) have the capacity for cardiac repair that appears to exceed their capacity for differentiation into cardiac myocytes.
T he quest to restore damaged organs is one of the major challenges in medicine. 1, 2 Recently, it has been demonstrated both experimentally 3 and in patients 4, 5 that the heart has the capacity to replace cardiac myocytes throughout life, but that this response is inadequate to compensate for major injuries such as myocardial infarction. These recent observations coupled with the description of endogenous cardiac stem cells 6 -9 have raised enthusiasm for tapping this intrinsic property therapeutically. Another avenue of cardiac cellbased therapy has used diverse adult cell sources such as fat, bone marrow, umbilical cord blood, and adipose tissue. 10, 11 Some of these cell types, particularly mesenchymal stem cells, have properties that could allow them to stimulate endogenous cardiac repair in a regulated manner. 12, 13 Bone marrow (BM)-derived MSCs regulate hematopoietic and other stem cell niches 14 -16 while maintaining substantial multilineage differentiation capacity. 17 Notably, recent studies document that interactions with MSCs are essential to the stimulation of in vitro proliferation and differentiation of other progenitor cell populations, in a process requiring direct cell-cell contacts. 16,18 -20 Currently, in experimental models, MSCs exert major functional recovery in the injured heart, 12, [21] [22] [23] [24] through incompletely understood mechanisms. [25] [26] [27] Here, we hypothesized that MSCs stimulate cardiac repair through cellautonomous effects that stimulate host myocardial precursor cells to amplify and differentiate into cardiomyocytes. 6, 22, 28 To address this prediction, we injected green fluorescent protein (GFP)-labeled, male porcine MSCs into the infarct and border zone in female pigs 3 days following myocardial infarction (MI); another group received injection of concentrated conditioned medium (CCM), so as to test whether secreted factors alone would be sufficient to stimulate host cardiac repair.
Methods
An expanded Methods section describing all procedures and protocols is available in the Online Data Supplement at http://circres.ahajournals.org.
This study was reviewed and approved by the University of Miami Institutional Animal Care and Use Committee and complies with all Federal and State guidelines concerning the use of animals in research and teaching as defined by The Guide For the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1985) .
For this study, 31 healthy female Yorkshire swine weighing 25 to 35 kg underwent experimental myocardial infarction (MI) followed by reperfusion (Online Figure I) . The study was conducted in 2 phases. In the first phase, 3 groups were studied: Yorkshire pigs received transendocardial injections (TEI) (Stiletto, Boston Scientific, Natick, Mass) of 75x10 6 GFP labeled MSCs (nϭ8), Placebo (nϭ8) or no injection (nϭ3) 3 days following the MI. Animals were euthanized at 24 hour (nϭ2 placebo and nϭ2 MSCs treated), 72 hour (nϭ3 placebo and nϭ3 MSCs treated) and 2 weeks (nϭ3 MSCs treated nϭ3 placebo and nϭ3 control) after transplantation to study the fate of the allogeneic cells.
In the second phase, 2 groups were studied: The Yorkshire pigs were randomized to receive TEI of 100ϫ10 6 cells of male GFP-labeled MSCs or their 10ϫ concentrated condition medium 3 days after MI and followed by MRI analyses (Siemens Symphony, Erlangen, Germany) at multiple time points (baseline; 2 days after MI; 4 days, 2 weeks, and 8 weeks after injection) to assess the amount of functional recovery. The animals were euthanized at 2 weeks (nϭ3 CCM and nϭ3 MSC-treated) and 8 weeks (nϭ3 CCM and nϭ3 MSC-treated) after injections.
GFP Transduction of MSCs
Passage 1 (P1) MSCs were plated in a T25-cm 2 flask and transduced with lentiviral green fluorescence protein (GFP). At approximately 50% confluence the media was removed and replaced with 5 mL of transduction media consisting of Alpha MEM plus 20% FCS plus 8 g/mL polybrene and 10 L of lentiviral vector LV-173GFP (Lentigen, Gaithersburg, Md). The culture flask was incubated for 72 hours total, with fresh transduction media being added every 24 hour. The next day the media was removed and Alpha MEM plus 20%FCS added to the culture. The flask was further incubated until confluent. Cultures were expanded with each passage of the GFPϩ MSC until sufficient numbers of MSC were obtained. The cells were then frozen in liquid nitrogen until needed. Before injection, the cells were thawed rapidly and washed to remove DMSO, then resuspended in PBS plus 1% human serum albumin to the required cell dose.
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Transendocardial Injections of MSCs
Delivery of the cells at the sites of myocardial injury was performed as previously described. 22 Briefly, left ventriculograms from 2 different angiographic projections (left [Ϫ30°] and right [ϩ30°] anterior oblique) were used to manually map the endocardial contours of the left ventricles in both projections. The infarcted myocardial zone (IZ) and border zone (BZ) were then delineated on the contours, and a total of 15 injections were performed in each animal, with each injection containing 0.5 mL of the injectate. Each injection was fluoroscopically guided to distribute cells evenly throughout the entire infarct and border zones.
Histology
For microscopic evaluation, the regions of interest were selected from each of the transverse ventricular sections based on CMRI and gross pathology findings: (1) . One sample from the middle of the scarred, infarcted tissue. (2) One sample containing the left border of the infarct along with nonscarred tissue; one sample containing the right border of the infarct along with nonscarred tissue (these 2 samples were defined as the border zones macroscopically). Microscopically, within these samples, border zones were defined as the areas that were 1 to 1 one-half high-power fields distant from scarred zones. (3) One sample from the posterior noninfarcted left ventricular (LV) wall. Confocal analysis was performed as previously described.
Statistical Analysis
All the values are presented as meansϮSEM. All analyses were performed by using the SPSS for Windows version 15.0 (SPSS Inc, Chicago, Ill). Differences between groups following immunohistological evaluation were compared by using 1-way ANOVA. Differences between groups in ejection fraction and infarct size based on cMRI were calculated by using 2-way repeated-measures ANOVA. The Tukey's test was used for the post hoc analysis. A level of PՅ0.05 was considered statistically significant.
Results
MSC Engraftment Reduces Infarct Size
As shown by serial cardiac MRI (cMRI), MI led to a reduced ejection fraction (27.9Ϯ1.1% and 25.8Ϯ3.1% for MSC and CCM groups respectively, PϭNS, PϽ0.001 versus baseline) and scar tissue that comprised Ϸ25% of the left ventricle (24.9Ϯ2.4% and 24.4Ϯ3.2% of the left ventricles of the MSC and CCM groups, respectively, PϭNS; Table and Figure 1 ).
Consistent with previous observations, [21] [22] [23] [24] as early as 4 days following TEI of MSCs, the absolute size of the myocardial infarct 29 was reduced by 8.3Ϯ1.8% (% LV mass) in the animals treated with MSCs, while remaining unchanged in the CCM group (Pϭ0.018; Figure 1 ). Eight weeks following MI, myocardial scar was reduced to 10.9Ϯ5.1% of the LV in the MSCtreated animals, whereas CCM caused a mild reduction in the absolute IS by 2.3Ϯ1.3% (Pϭ0.002 between groups) ( Figure  1A ). In addition, by 2 weeks the MSC group had a significant improvement in EF compared to post-MI (PϽ0.05), which persisted through the 8-week follow-up period ( Figure 1B ).
Localization of Injected MSCs in Infarcted Hearts
Engraftment and lineage tracing of transplanted MSCs were assessed with confocal immunofluorescence. As determined by both GFP and Y-chromosome tags, MSCs occupied IZ and BZ but not the healthy, remote areas of the infarcted myocardium. Interestingly, whereas MSCs lacked markers of cardiovascular lineage in vitro ( Figure 2A Y-chromosomeϩ tags colocalized with the endothelial cellspecific markers KDR and factor VIII-related antigen. Importantly, differentiation of MSCs into vascular phenotype did not occur during the first 24 hour, but by 72 hour 79Ϯ23 GFP ϩ cells/cm 3 exhibited commitment to vascular lineage ( Figure 3B ; Online Figures IV and VII). Two weeks later, coronary vascular chimerism was still present within the myocardium ( Figure 3E ).
MSCs Engraftment Induces C-kit ؉ CSC Recruitment
Next, we tested the hypothesis that MSCs, in addition to direct tissue replacement could also contribute to myocardial repair by supporting endogenous CSCs to regenerate myocardium. Interestingly, 2 weeks after MSC injection, the MSC-treated hearts exhibited chimeric clusters containing both immature MSCs of exogenous origin and endogenous CSCs (Figures 4, 5; Online Figure III , A through C), defined by the expression of the stem cell factor-receptor, c-kit. 6, 8 These clusters were mainly localized within the IZ and BZ but not the noninfarcted, remote myocardium or the non-MSC treated hearts; important cell-cell interactions between the MSCs and endogenous CSCs could be documented ( Figure XII ). C-kit ϩ cells lacked GFP confirming that they did not arise from the MSCs (Figure 4D , 4G, and 4H and Figure  5 ). Quantification of c-kit ϩ cells in infarct hearts illustrated sporadic distribution during the first 3 days after transplantation similar in MSC and CCM groups. At 2 weeks following TEI, endogenous c-kit ϩ CSCs increased 20-fold in MSC but not CCM treated animals ( Figures 4A and 5 ). In addition, CSCs formed potential connexin-43 mediated gap junctions and N-cadherin mechanical connections with other c-kit ϩ cells, adult cardiomyocytes, and with GFP ϩ MSCs (Figures 4 and 5; Online Figure XII) , and formed structures that resemble cardiac stem cell niches. 6 -9 Further immunohistochemical characterization demonstrated that a number of CSCs coexpressed MDR1 and GATA-4, indicating a cardiac lineage commitment ( Figure 4E ). The number of cardiac committed CSCs increased 2-fold in the IZ and 15-fold in the BZ of MSC-treated animals compared to animals receiving either CCM, noncellular vehicle alone, and untreated controls (Figure 4B ). There were no differences between groups in the noninfarcted zones, indicating the presence of an active endogenous repair mechanism targeting the damaged zones of the treated hearts ( Figure 4B ). Finally, by 8 weeks the level of endogenous CSCs decreased to baseline post-MI levels, and were detected as scattered, isolated cells with no differences observed between treatment groups ( Figure 4A ).
MSCs Stimulate Cardiomyocyte Cell Cycling
In addition to activating c-kit ϩ cardiac precursors to enter cardiomyocytic lineages, MSCs also stimulated cardiomyocyte replication ( Figure 6 and Online Figure IX ). Host cardiomyocyte turnover peaked at 2 weeks after therapy as indicated by the expression of the mitotic marker of serine 10-phosphorylated Histone-H3 (phospho-H3), and was 4-fold greater in the IZ and BZ of the MSCs treated hearts compared to CCM group ( Figure 6A ). The number of mitotic myocytes in the MSC-group was significantly higher in both the IZ (14,220Ϯ4750 versus 3,480Ϯ590 cardiomyocytes/cm 3 , Pϭ0.03) and BZ (12,810Ϯ3720 versus 3,190Ϯ470 cardiomyocytes/cm 3 , Pϭ0.005) compared to the CCM-treated animals ( Figure 6A ). Colocalization of GFP and/or Y-chromosome tags with phospho-H3 ϩ cardiomyocytes could be rarely documented, indicating that the majority of amplifying cardiomyocytes detected were of host origin (data not shown). The levels of cycling myocytes in the MSC-treated group decreased by 2 months, and no differences could be observed between groups ( Figure 6B ). However, the total number of newly formed cardiomyocytes of both donor and host origin was still greater in the BZ of the MSCs treated animals compared to the CCM-treated animals (2,310Ϯ640 versus 450Ϯ120 total new cardiomyocytes/cm 3 in the BZ of MSCs and CCM-treated respectively, Pϭ0.02), illustrating that direct tissue replacement by differentiated MSCs contributed significantly to the regeneration of the BZ areas ( Figure 6B ). 
MSCs Stimulate Proliferation and Myocardial Commitment of c-kit ؉ CSCs In Vitro
We next performed in vitro experiments to study the function and origin of endogenous CSCs in relation to MSCs ( Figure  7 and Online Figure XIII) . Fresh (nϭ12) or cryopreserved (nϭ26) endomyocardial biopsies from porcine hearts were cultured for one week with or without MSCs as feeder layers ( Figure 7B -7D and Online Figure XIII , A-C). In additional control experiments, MSCs were cultured under the same conditions without a myocardial biopsy. After 3 days, myocardial biopsies became infiltrated by MSCs and adhered to the MSC monolayers (Online Figure XIII, B) . In contrast, biopsies cultured without MSCs remained in suspension (Online Figure  XIII, A) . Within one week organotypic cocultures became confluent, and purification by repeated immune panning 30 illus-trated that the number of GFP-negative, c-kit ϩ cells egressing from the biopsy were 6-fold greater compared to biopsies cultured alone (Figure 7) . These cells were CD68 neg , small, semiadherent and self-renewing ( Figure 7 and Online Figure  XIII) . As expected, c-kit ϩ cells could not be harvested from MSC-control cultures (Figure 2) . A mean of 19,159Ϯ6,506 versus 3347Ϯ1,519 c-kit ϩ cells were purified from biopsies cultured with and without MSCs respectively (Pϭ0.003). Similar to our in situ findings, immunocytochemical analysis documented the development of connexin-43 mediated cell-cell interactions between GFP ϩ and c-kit ϩ cells ( Figure 7B) . In contrast, c-kit ϩ cells purified from biopsies cultured without MSCs had a large, antigen-presenting cell-morphology that did not proliferate ( Figure 7D ).
In comparison to previous studies, 6 -9,31,32 purification of c-kit ϩ CSCs from single biopsy samples was accelerated by coculture with MSCs, and facilitated an outgrowth of highly myocardiocytic CSCs; greater than 90% of the cells expressed the cardiac transcription factors Nkx2.5 and GATA-4 and the ATP-binding cassette transporter MDR1 while lacking expression of the VEGF-receptor, KDR (Figure 7 
Porcine CSCs Differentiate Into Myocytes by Coculturing With Neonatal Cardiomyocytes
To test the capacity of the CSCs to differentiate into myocytes we performed cocultures with neonatal rat cardiomyocytes (NRCMs). Porcine CSCs were seeded on transwell membranes, and placed on top of NRCM monolayers. After 3 to 4 days in coculture, CSCs illustrated phenotypic characteristics of mature cardiomyocytes, evidenced by a striated cytoskeleton expressing cardiac troponin-I (Online Video II). Importantly, differentiation of CSCs into cardiomyocytes in a transwell culture system which prevents the development of direct cell contact with NRCMs, excludes cell-fusion and demonstrates a cardiomyocytic phenotype of this adult cardiac precursor cell type.
Discussion
Here, we demonstrate that bone marrow derived MSCs, when injected into the post-myocardial infarct porcine heart, facilitate substantial cardiac recovery involving host cell-based repair, as well as MSC engraftment and differentiation. Differentiation of MSCs occurs acutely after transplantation, and MSCs stimulate endogenous cardiomyocyte turnover in 2 likely related ways: first, by stimulating endogenous c-kit ϩ CSCs; and second, by enhancing cardiomyocyte cell cycling. Together these phenomena represent the spectrum of changes necessary for the amplification and differentiation of new adult cardiomyocytes. The interaction between cardiac derived c-kit cells and bone marrow derived MSCs could be replicated in vitro, where the coculturing amplified c-kit cell expansion and differentiation.
Efficacy of MSCs
Several previous studies from our group [21] [22] [23] [24] 33 and that of others 34 -36 demonstrate in large animal models major degrees of infarct size reduction and functional recovery with MSC cell therapy. We have previously documented reappearance of myocardial tissue in the border zones of infarction including a rim of tissue on the endocardial surface 21 that is associated with improved tissue perfusion 24 and recovery of regional function. 21, 23 Despite the reproducible demonstration of major cardiac recovery with MSC therapy and as shown in both animal models and humans, 13 the underlying mechanism of action has been a challenge to demonstrate given the rarity of differentiated MSC-derived myocytes in the post infarction heart.
In the present study, we demonstrate a multifold mechanism of action for this effect that includes MSC engraftment and trilineage differentiation. Importantly, MSCs interact with host cardiac progenitor cells, promoting their recruitment and/or expansion and differentiation. In addition, there is evidence of extensive myocyte mitosis which very likely represents the terminal stage of cycling of cardiac progenitor cell-derived myocytes. 5 It is also possible that this observation could represent cell cycling of mature myocytes as has been suggested to occur in the zebrafish. 37, 38 The engraftment of MSCs appears to be necessary as tissue recovery is not achieved with the injection of MSC conditioned media.
Direct Versus Indirect Tissue Replacement Following MSC-Based Cardiac Repair
The present findings argue against a solely paracrine mechanism for MSC stimulated cardiac repair and strongly support that transplanted MSCs engraft and respond directly to cues of injury in infarcted myocardium. By using dual labeling with GFP and sex mismatch strategies to trace allograft fate, we document that transplanted MSCs exhibit features of differentiated cardiomyocytes suggesting direct replacement of myocardial tissue by chimeric CMs. Without excluding the possibility of cell fusion between exogenous and endogenous cells, our data indicate that MSCs generate new CMs and that this process occurs during the first 24 hours following transplantation. However, even though the newly produced chimeric CMs last for at least 2 months and contribute significantly to the total number of new CMs regenerating the injured heart, their number remains unlikely to account in total for the extensive degree of cardiac recovery documented by cMRI. Accordingly we demonstrate alternative mechanisms for cell autonomous, MSC mediated cardiac repair. MSCs stimulated a series of secondary endogenous responses that caused substantial amounts of adult CMs and, more importantly, immature CSCs to proliferate and replenish the damaged regions with new CMs of host origin.
Our findings permit an estimate of the degree of myocardial tissue regenerated by varying mechanisms. Using rates of appearance of various cell types as a percentage of total new myocytes within the infarct border zones, we estimate that MSCs could contribute up to Ϸ8% of the newly formed cardiomyocytes. 39, 40 Chimeric cardiomyocytes require less than 2 weeks to reach a mature appearance and their presence at 2 months argues that they are not rejected. However, a greater extent of cardiac repair originates endogenously. We document the concerted appearance of c-kit ϩ CSCs and phospho-H3 ϩ mitotic CMs 5,37 (likely representing transient amplifying myocytes originating from CSCs) that peaked 2 weeks after therapy. Together, CSCs and mitotic CMs are estimated to contribute at least 45% of the new myocardial mass. Interestingly, the abundance of both CSCs and transient amplifying myocytes decline in parallel by 8 weeks further suggesting a linkage between the appearance of CSCs and transient amplifying cells. 5, 41 This phenomenon strongly supports the notion that repeated application of cell therapy may lead to further declines in scar tissue within injured myocardium.
None of the above effects occurred when CCM was used as treatment following MI, highlighting that even though paracrine signaling can be a major contributor to cardiac regeneration, the degrees of repair that occur with cell injections cannot be achieved with single applications of factors secreted from MSCs. Indeed, although this may simply be an issue of pharmacokinetics as specific paracrine and autocrine pathways are shown to stimulate endogenous tissue repair, MSC delivery clearly provides an enormous advantage in that a single delivery provides a long-standing and sustained biological effect.
These findings offer a broader perspective on the biology of regeneration and should be viewed in the context of several other major advancements. First, substantial efforts are underway to genetically manipulate MSCs to enhance their survival and/or to use them as delivery vectors 42 ; indeed our findings showing cell-cell coupling of MSCs support this approach. Second, successful cardiac repair in our model was based on interaction of administered MSCs with host cells, and in this regard there are other attractive candidates for host cells such as recently described endogenous multipotent circulating progenitors. 43 As mentioned above, a major hypothesis underlying regenerative effects of MSCs has been termed the "paracrine hypothesis" in which a number of paracrine 44 and autocrine factors such as nucleostemin 45 drive regeneration of injured hearts. Our findings are not at odds with this hypothesis, and likely MSCs orchestrate a broad array of reparative effects. As a corollary to the paracrine hypothesis, MSCs release immunomodulatory cytokines as part of their secretome 46, 47 that could enhance long term graft tolerance following heart transplantation. Finally, it is highly likely that MSCs will have therapeutic potential in a broad array of cardiac disorders in addition to ischemic heart disease.
MSCs Support Expansion of the Local CSCs Pool and Enhance Their Cardiomyocytic Potentials
Two key questions that are addressed here warrant mention. First, is whether the clusters of c-kit ϩ CSCs present in the MSC-treated hearts represent cells mobilized from extracardiac tissues such as the bone marrow and circulating blood, or whether they originated from the heart. Secondly, we ad- dressed the differentiation capacity of these endogenous cells. To address the potential cardiac origin of the c-kit cells, we cocultured heart biopsies on MSC lawns demonstrating that the MSC-feeder layers stimulated the expansion of c-kit ϩ CSCs. The CSCs that resulted from MSC coculture were more than 90% positive for Nkx2-5, a phenotype previously found only in the developing fetal hearts. In addition, the adult CSCs exhibit significantly enhanced cardiomyocytic potentials compared to CSCs that exist in the adult myocardium, and suggest that bone marrow MSCs may provide significant information to link cardiac development to repair. Thus, endogenous CSCs clusters detected in situ following MSCs implantation seem unlikely to originate from distant tissues such as the bone marrow, because their isolation from single heart biopsies suggests they stem from the cardiac pool. Although our results do not exclude the possibility of mobilization from distant sources 43 (indeed the circulating multipotent cells could represent a master reservoir of tissue specific precursors), these results confirm the presence of precursor reservoirs within the heart itself, and provide evidence that therapeutic CSCs can be harnessed from endomyocardial biopsies. With regard to differentiation, both in vivo and ex vivo studies document lineage commitment and potential differentiation of c-kit cells.
Timing and Mode of Delivery
It is not firmly established whether selecting different routes, timing, and doses when delivering the MSCs would have a greater or less impact on prevention of remodeling following MI. Comparing our previous [21] [22] [23] [24] 33 and present laboratory findings, we believe that hastening 24, 36 or delaying 22, 33, 34 cell therapy may not have as a robust an effect as to the targeted delivery of MSCs 3 days after MI. 21, 23 Importantly, we have found that late treatment following full infarct healing, with the goal of reversing infarct remodeling can produce substantial recovery. In this setting, 22, 33 the degree of infarct size reduction, although substantial, is not as great as that observed with treatment in the early postinfarction period.
Certain technical features of our study warrant mention. We used a transendocardial injection in a reperfused MI model. Most investigators have used intravenous or intracoronary routes to deliver cells in infarcted heart tissue 48 assuming that, in this way, important paracrine actions of the infused cells could still be harnessed without risking unnecessary myocardial damage. However, our study provides novel insights to delivering cellbased therapies and, besides providing further evidence that TEIs can be a safe and efficient method to deliver MSCs, 21, 23 suggests that TEIs delivery to the infarct border zone may provide an optimal substrate for cell engraftment and interaction with host cells. Indeed, it is attractive to speculate that delivery of boluses of MSCs may provide an ideal mechanism to foster reconstitution of cardiac stem cell niches. 6, 12 
Study Limitations
With regard to the adequacy of the conditioned media generated from porcine MSCs cultures, we used the technique described by Maitra et al 49 with minor modifications to concentrate the media 10-fold. We acknowledge that we cannot fully rule out the importance of secreted factors contained within the conditioned media. Moreover, it is well described that several factors secreted by MSCs are shown to recruit CSCs. 50 The fact that our CCM produced little to no reparative effects could be attributable to a pharmacological effect and that single dosing could not produce the sustained effects observed with MSCs. Work is ongoing to define the factors produced by MSCs that stimulate endogenous repair in cell nonautonomous manners.
Conclusion
Together, these results offer insights into the mechanism of action of a cell-based therapy whereby significant cardiac repair occurs in the absence of a degree of engraftment and The fraction of the c-kit ϩ cells that were produced from the cocultures was 3.4Ϯ0.9% of the total cell number in coculture versus 5.0Ϯ2.2% of the cells without coculture. However, there were 10-fold more cells with coculture than without, yielding many more c-kit ϩ cells (1.01ϫ10 6 cells/coculture versus 0.9ϫ10 5 cells/biopsy alone panned 1 week after plating the organotypic cultures in each group). In comparison, coculture with MSCs egress small, semiadherent CSCs that renew their population constantly (C). E and F, Immunocytological stainings of c-kit ϩ CSCs purified and expanded from the organotypic cocultures with MSCs illustrate the high percentage of c-kit ϩ cells coexpressing MDR1 (E, yellow) and NKX2-5 (F, white), while lacking the mast-cell surface epitope CD68 (E, white). Mean valuesϮSEM (nϭ19 each). *PϽ0.005. differentiation sufficient to account for the degree of cardiac functional recovery. Moreover, these findings require a broadening of our therapeutic perspective solely away from cells with maximum differentiation capacity to those that have a spectrum of activities that include cell-cell interactions. As such, cell-cell interactions may offer therapeutic synergies not fully embodied in a single cell preparation. Thus, we suggest that MSCs may replenish or restore cardiac stem cell niches lost or injured during myocardial infarction.
